Literature DB >> 16341734

[Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

S Happe1, W Paulus.   

Abstract

The restless legs syndrome (RLS) is a clinical diagnosis based on the four essential criteria defined by the International Restless Legs Syndrome Study Group (IRLSSG). An idiopathic form can be separated from a symptomatic form. Neurophysiological studies have investigated the pathophysiology of the idiopathic RLS or have been used to exclude a symptomatic cause, in particular polyneuropathy. So far cortical excitability changes, corticomotor, somatosensory and auditory pathways, spinal cord excitability, B-wave rhythm and cycling alternating pattern, as well as reflex mechanisms have been investigated by electroencephalography, evoked potentials, Bereitschaftspotentials, nerve conduction and thermal threshold measurements, electromyography, transcranial Doppler sonography, measurements of the spinal flexor reflex as well as neuroimaging techniques. The etiology of the RLS cannot be revealed by these methods, neurophysiological studies in RLS are, however, useful for a better understanding of the pathophysiology and for exclusion of a polyneuropathy or other symptomatic causes. In addition to neurophysiological investigations, small fiber neuropathy, which seems to be a more common finding in RLS patients than expected to date, may need biopsy for confirmation. This review will focus on investigations of the different systems involved with diverse neurophysiological methods.

Entities:  

Mesh:

Year:  2006        PMID: 16341734     DOI: 10.1007/s00115-005-2025-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  88 in total

1.  Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

2.  Restless Legs Syndrome: scoring criteria for leg movements recorded during the suggested immobilization test.

Authors:  M Michaud; G Poirier; G Lavigne; J Montplaisir
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

3.  Epidemiology of restless legs symptoms in adults.

Authors:  B Phillips; T Young; L Finn; K Asher; W A Hening; C Purvis
Journal:  Arch Intern Med       Date:  2000-07-24

4.  Somatosensory and brainstem auditory evoked responses in sleep-related periodic leg movements.

Authors:  S S Mosko; K L Nudleman
Journal:  Sleep       Date:  1986       Impact factor: 5.849

5.  Bereitschaftspotential in idiopathic and symptomatic restless legs syndrome.

Authors:  C Trenkwalder; S F Bucher; W H Oertel; D Proeckl; H Plendl; W Paulus
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1993-04

6.  Idiopathic restless legs syndrome: abnormalities in central somatosensory processing.

Authors:  Jörn Schattschneider; Andre Bode; Gunnar Wasner; Andreas Binder; Günther Deuschl; Ralf Baron
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

7.  Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology.

Authors:  Sean J Pittock; Timothy Parrett; Charles H Adler; Joseph E Parisi; Dennis W Dickson; J Eric Ahlskog
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

8.  Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.

Authors:  Svenja Happe; Cornelia Sauter; Gerhard Klösch; Bernd Saletu; Josef Zeitlhofer
Journal:  Neuropsychobiology       Date:  2003       Impact factor: 2.328

9.  Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.

Authors:  Ilonka Eisensehr; Bruce L Ehrenberg; Silvia Rogge Solti; Soheyl Noachtar
Journal:  J Neurol       Date:  2004-05       Impact factor: 4.849

10.  The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study.

Authors:  Sarah von Spiczak; Alan L Whone; Alexander Hammers; Marie-Claude Asselin; Federico Turkheimer; Tobias Tings; Svenja Happe; Walter Paulus; Claudia Trenkwalder; David J Brooks
Journal:  Brain       Date:  2005-02-23       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.